

# Adipose-Derived Stem Cells (ADSC) and Aesthetic Surgery: A Mini Review

Davood Mehrabani<sup>1</sup>, Golshid Mehrabani<sup>2</sup>, Shahrokh Zare<sup>1</sup>, Ali Manafi<sup>3\*</sup>

1. Stem Cell and Transgenic Technology Research Center, Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
2. Student Research Committee, School of Dentistry, International Kish Branch, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Plastic Surgery, Tehran University of Medical Sciences, Tehran, Iran
4. Tehran, Iran

## ABSTRACT

In cell therapy and regenerative medicine, a reliable source of stem cells together with cytokine growth factors and biomaterial scaffolds seem necessary. As adipose tissue is easy accessible and is abundant source of adult stem cells and can differentiate along multiple lineages, it can be considered as a good candidate in aesthetic medicine. The clinical application of adipose-derived stem cells (ASCs) is reviewed in this article.

## KEYWORDS

Adipose, Stem cell, Aesthetic medicine

Please cite this paper as:

Mehrabani D, Mehrabani G, Zare Sh, Manafi A. Adipose-Derived Stem Cells (ADSC) and Aesthetic Medicine: A Mini Review. *World J Plast Surg* 2013;2(2): 65-70.

## INTRODUCTION

Developments in stem cell science, stem cell-associated growth factors, and regenerative medicine in recent years may provide the opportunity for use of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and postnatal adult stem cells in repair of tissue injuries and, eventually, in replacement of organs.<sup>1</sup>

Application of cellular therapy and regenerative medicine is rapidly growing, but for regenerative medicinal purposes, stem cells should meet several criteria: (i). They could be provided in abundant quantities (millions to billions of stem cells); (ii). They could be differentiated into many cell lineages in a regulatable and reproducible way; (iii). They could be harvested by minimally invasive techniques; (iv). They could safely and effectively be used in either an autologous or allogeneic host; and (v). They could be produced according to current Good Manufacturing Practice guidelines.<sup>2</sup>

Among stem cells, ESCs have the potential of extensive self-renewal, expansion and differentiation into any type of somatic tissues making them for future use in regenerative medicine.<sup>1</sup> iPSCs as the other group of stem cells are derived from differentiated cells including skin fibroblasts and keratinocytes by transduction with a combination of many transcription factors involved in reprogramming. These cells are phenotypically and functionally indistinguishable from ES cells. However, their production is not dependent on a source of embryos.<sup>3</sup>

### \*Correspondence Author:

Ali Manafi, MD,  
Associate Professor of Department of  
Plastic Surgery,  
Tehran University of Medical  
Sciences,  
Tehran, Iran

Email: dramanafi@yahoo.com

Received: Oct 1, 2012

Accepted: May 1, 2013

iPSCs could potentially be used in construction of tissue-engineered skin even several limitations were seen in practical use of iPSCs and ESCs including cellular regulation of teratoma formation, immune concerns and ethical considerations for them and problems in genetic manipulation of iPSCs.<sup>1,4</sup>

The third group of stem cells are postnatal adult stem cells which by their nature are immuno-compatible, and there are no ethical concerns for their use.<sup>4</sup> They are called multipotent mesenchymal stem cells (MSCs) and are non-hematopoietic adult stem cells of mesodermal derivation seen in many postnatal organs and connective tissues.<sup>4</sup> MSCs either derived from bone marrow or adipose tissue were shown to be suitable candidates for cell therapy. Among them, bone marrow MSCs (BM-MSCs) are a heterogeneous group of multipotent progenitor cells with the potential of self-renewal and differentiation into cells with ectodermal, mesodermal and endodermal characteristics.<sup>5</sup> They have the intrinsic potential to leave the bone marrow, circulate in the blood and home to injured tissues.<sup>6</sup> BM-MSCs are a standard population in regenerative medicine due to their high differentiation capacity and low morbidity during harvesting. But harvesting in bone marrow aspiration is still considered as a painful procedure and the quantity of cells acquired is usually low.<sup>7</sup>

MSCs, with identical characteristics to BM-MSCs were isolated from various tissues such as periosteum,<sup>8</sup> trabecular bone,<sup>9</sup> synovial membrane,<sup>10</sup> pericytes,<sup>11</sup> peripheral blood,<sup>12</sup> skeletal muscle,<sup>13</sup> skin,<sup>14</sup> periodontal ligament,<sup>15</sup> deciduous teeth,<sup>16</sup> and umbilical cord.<sup>17,18</sup>

Based on the limitations with these BM-MSCs including low number of harvested cells, limited amount of harvested tissues and donor site morbidity or patient discomfort in providing a sample, there was a need for ex vivo expansion or further manipulation of these cells before their preclinical or clinical used to satisfy the safety and efficacy requirements.<sup>19</sup> Therefore, adipose tissue was considered an attractive alternative source which can be provided in large quantities from adipose tissue fragments.<sup>20</sup>

Based on the reports of the American Society for Aesthetic Plastic Surgery, about five hundred thousand elective liposuction surgeries were undertaken each year in the United States.<sup>21</sup> So adipose tissue has successfully been used as

autologous fat grafts for structural fat grafting in lip, facial, and hand rejuvenation and body contour improvement, but a relatively lower level of attention was directed to their application in cosmetic, plastic, and reconstructive surgery.<sup>22-26</sup>

Adipose tissue is considered as a source of MSCs, termed adipose-derived stem cells (ASCs). They are ubiquitous and easily obtained in large quantities with little donor site morbidity or patient discomfort<sup>19</sup> making the use of autologous ASCs an appropriate research tool and cellular therapy.<sup>27</sup> Lipoaspirates provide an easily obtainable source of ASCs at a frequency of 1:100 to 1:1500 cells exceeding the frequency of MSCs from bone marrow 500-fold, while 1 g of adipose tissue was shown to yield nearly 5,000 ASCs.<sup>28</sup>

ASCs have also the potential for banking as an alternative or complement to cord blood banking for many therapeutic applications in which MSCs could be used.<sup>29</sup> Several researches were undertaken on tissue remodeling and differentiation of ASCs into specialized somatic cell types to replace damaged organs and tissues.<sup>30</sup> They were demonstrated to be immunoprivileged<sup>31</sup> and seem to be more genetically stable in long-term culture<sup>32</sup> in comparison with BM-MSCs.<sup>33</sup>

Adipose tissue is composed of mature adipocytes constituting about 90% of the tissue volume, and a stromal vascular fraction (SVF) including fibroblasts, endothelial cells, preadipocytes, vascular smooth muscle cells, lymphocytes, resident monocytes/macrophages and ASCs.<sup>34</sup> ASCs have mesodermal origin, but they have the potential to differentiate into several lineages of osteogenic, chondrogenic, adipogenic, cardiomyogenic, myogenic, and neurogenic cells.<sup>28</sup> They can differentiate into tissues of endo- and ectodermal lineages such as hepatocytes, pancreatic islet cells, endothelial cells, neural cells, and epithelial cells too.<sup>28</sup>

It was shown that ASCs harvested from superficial abdominal regions are significantly more resistant to apoptosis than other parts.<sup>35</sup> ASCs are available within the brown adipose tissue.<sup>36</sup> Fresh SVF cells were shown to be heterogeneous with putative ASCs (CD31<sub>-</sub>, CD34<sub>β</sub><sub>-</sub>, CD45<sub>-</sub>, CD90<sub>β</sub>, CD105<sub>-</sub>, and CD146<sub>-</sub>), endothelial (progenitor) cells (CD31<sub>β</sub>, CD34<sub>β</sub>, CD45<sub>-</sub>, CD90<sub>β</sub>, CD105<sub>-</sub>, and CD146<sub>β</sub>), vascular smooth muscle cells or pericytes (CD31<sub>-</sub>, CD34<sub>β</sub><sub>-</sub>, CD45<sub>-</sub>, CD90<sub>β</sub>, CD105<sub>-</sub>,

and CD146b), and hematopoietic cells (CD45b) in uncultured conditions.<sup>37</sup> Also, freshly SVF cells and early passage of ASCs were demonstrated to present higher levels of human leukocyte antigen-DR (HLA-DR), CD117 (c-kit), and stem cell-associated markers such as CD34, along with lower levels of stromal cell markers such as CD13, CD29 (b1 integrin), CD44, CD63, CD73, CD90, CD105, and CD166.<sup>37</sup> Pericyte markers are also expressed by ASCs such as platelet-derived growth factor (PDGF) receptor- $\beta$ , smooth muscle  $\alpha$ -actin, and neuroglial proteoglycan 2,<sup>38</sup> while the markers shared by ASCs and MSCs include CD13, CD29, CD44, CD58, and CD166. ASCs like other MSCs can show telomerase activity even lower than the cancer cell lines revealing the capacity of ASCs for self-renewal and proliferation.<sup>39</sup> Puissant *et al.*<sup>40</sup> reported the absence of HLA-DR expression and the immunosuppressive properties of ASCs. Fang *et al.* showed that severe steroid-refractory acute graft-versus-host disease (GVHD) could be treated with ASCs from HLA-mismatched donors.<sup>41</sup>

Therefore, cell therapy and regenerative medicine have opened a window as an interdisciplinary field of clinical use of stem cells focussing on the repair, replacement or regeneration of cells, tissue or organs to restore impaired function due to disease, congenital deformities, trauma and ageing. In regenerative medicine, many technological approaches are combined such as stem cell transplantation, gene therapy, the use of soluble molecules, tissue engineering and the reprogramming of cell and tissue types.<sup>42</sup> Surgeons have tried to market "stem cell face-lifts" when in fact the procedure involving merely facial fat injections.<sup>43</sup>

In regenerative medicine, tissue engineering combines stem cells, growth factors, and biomaterials for repair of failing organs using fabricate biocompatible scaffolds which would promote cell infiltration and angiogenesis together with production of highly purified, bioactive cytokines in large quantity.<sup>44</sup>

ASC therapy in regenerative laboratories and clinical settings was used in treatment of wound beds with a poor blood supply and for healing of radiation injuries. The safety and efficacy of ASCs in reconstructive medicine were evaluated in many clinical trials. The number of these trials had an increasing trend from a total of nine in December 2009 to 18 by May 2010. These trials investigated

the efficacy of ASCs in treatment of many diseases and disorders (<http://clinicaltrials.gov>).

ASCs were also evaluated in clinical case studies for soft tissue augmentation,<sup>45</sup> bone tissue repair,<sup>46</sup> graft-versus-host disease,<sup>47</sup> immunosuppression<sup>48</sup> and multiple sclerosis.<sup>49</sup> Augmentation of soft-tissue deformities using scaffolds seeded with ASCs were previously reported.<sup>50</sup> ASCs or preadipocytes were used as seeded ones on hyaluronic acid-based scaffolds in 12 volunteers resulting into matrix deposition and cell infiltration. But the hyaluronic acid-based scaffolds could not support pre-adipocyte survival and were not inductive towards adipose tissue formation.<sup>50</sup>

Yoshimura *et al.* used adipose-derived SVF cells in augmentation of soft tissues by cell-assisted lipotransfer (CAL)<sup>51</sup> in treatment of breast augmentation and facial lipoatrophy. In facial lipoatrophy, no complications or adverse side effects were noticed.

In augmentation of the breast, the augmentation of breast was successful and had satisfactory clinical results without any major complications too.

In regenerative medicine, skin is an attractive model organ for the use of stem cells. Recent breakthroughs in understanding the role of ASCs in wound healing and tissue regeneration have lead to new options for treating difficult wounds. It was shown in a diabetic animal that the topical administration of autologous ASCs together with a type I collagen sponge matrix could accelerate the healing of diabetic ulcers.<sup>52</sup>

Another clinical study on treatment of radiation-induced tissue damages by administration of human ASCs resulted into progressive improvement in tissue hydration and new vessel formation due to the release of growth factors such as VEGF and HGF leading to the subsequent angiogenesis and proliferation of keratinocytes or dermal fibroblasts.<sup>53</sup>

It was shown that epidermal stem cells might provide a prominent source of multipotent stem cells to replace damaged tissues and lead to wound healing<sup>54</sup> including a basal keratinocyte population found in the interfollicular epithelium and stem cells residing in the bulge region of the hair follicle.<sup>55</sup> The other reservoir of skin stem cells is the bulge region of the ORS of hair follicles. Stem cells provided from hair follicles could be differentiated into the ORS of the hair follicle.<sup>56</sup>

The application of ASCs and other stem cells

in treatment of many medical conditions has been reflected in several mass media. But it is of great importance in scientific and medical communities to balance the hope from the hype and just time will clarify whether, someday, healthy subjects will voluntarily undergo liposuction to donate fat identically when they donate blood.<sup>56,57</sup> Also as ASCs have gained popularity in regenerative medicine, improvement in methods to assess their reproducibility, safety and quality of the vitro expanded stem cells is important. In addition, producing cells that are genetically stable is a step towards getting insurance that the cells would not transform, leading to genetically aberrated progeny when transplanted into the recipient.<sup>57</sup>

Based on the available data in literature, further studies are needed in both basic and clinical sciences on application of ASCs to clarify if ASC-supplemented fat transplants are really safe and effective and also on the costs, graft survival, predictability of findings, ease of procedures and aesthetic outcomes.

### CONFLICT OF INTEREST

The authors declare no conflict of interest.

### REFERENCES

- 1 Lenoir N. Europe confronts the embryonic stem cell research challenge. *Science* 2000;**287**:1425–1427.
- 2 Gimble JM. Adipose tissue-derived therapeutics. *Expert Opin Biol Ther* 2003;**3**:705–713.
- 3 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006;**126**:663–676.
- 4 Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. *Nat Rev Cancer* 2011;**11**:268–277.
- 5 Battula VL, Bareiss PM, Treml S, Conrad S, Albert I, Hojak S, Abele H, Schewe B, Just L, Skutella T, Bühring HJ. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. *Differentiation* 2007;**75**:279–291.
- 6 Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. *Blood* 2004;**104**:3581–3587.
- 7 Jaiswal RK, Jaiswal N, Bruder SP, Mbalaviele G, Marshak DR, Pittenger MF. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. *J Biol Chem* 2000;**275**:9645–9652.
- 8 Choi YS, Noh SE, Lim SM, Lee CW, Kim CS, Im MW, Lee MH, Kim DI. Multipotency and growth characteristic of periosteum-derived progenitor cells for chondrogenic, osteogenic, and adipogenic differentiation. *Biotechnol Lett* 2008;**30**:593–601.
- 9 Song L, Young NJ, Webb NE, Tuan RS. Origin and characterization of multipotential mesenchymal stem cells derived from adult human trabecular bone. *Stem Cells Dev* 2005;**14**:712–721.
- 10 De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum* 2001;**44**:1928–1942.
- 11 Feng J, Mantesso A, Sharpe PT. Perivascular cells as mesenchymal stem cells. *Expert Opin Biol Ther* 2010;**10**:1441–1451.
- 12 Shi M, Ishikawa M, Kamei N, Nakasa T, Adachi N, Deie M, Asahara T, Ochi M. Acceleration of skeletal muscle regeneration in a rat skeletal muscle injury model by local injection of human peripheral blood-derived cd133-positive cells. *Stem Cells* 2009;**27**:949–960.
- 13 Dodson MV, Hausman GJ, Guan L, Du M, Rasmussen TP, Poulos SP, Mir P, Bergen WG, Fernyhough ME, McFarland DC, Rhoads RP, Soret B, Reecy JM, Velleman SG, Jiang Z. Skeletal muscle stem cells from animals I. Basic cell biology. *Int J Biol Sci* 2010;**6**:465–474.
- 14 Belicchi M, Pisati F, Lopa R, Porretti L, Fortunato F, Sironi M, Scalamogna M, Parati EA, Bresolin N, Torrente Y. Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. *J Neurosci Res* 2004;**77**:475–486.
- 15 Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahimi J, Young M, Robey PG,

- Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004;**364**:149–155.
- 16 Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S. Shed: Stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci USA* 2003;**100**:5807–5812.
  - 17 Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. *Stem Cells* 2007;**25**:1384–1392.
  - 18 Musina RA, Bekchanova ES, Sukhikh GT. Comparison of mesenchymal stem cells obtained from different human tissues. *Bull Exp Biol Med* 2005;**139**:504–509.
  - 19 Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: Implications for cell-based therapies. *Tissue Eng* 2001;**7**:211–228.
  - 20 Zuk PA. Tissue engineering craniofacial defects with adult stem cells? Are we ready yet? *Pediatr Res* 2008;**63**:478–486.
  - 21 Housman TS, Lawrence N, Mellen BG, George MN, Filippo JS, Cerveny KA, DeMarco M, Feldman SR, Fleischer AB. The safety of liposuction: results of a national survey. *Dermatol Surg* 2002;**28**:971–978.
  - 22 Coleman SR. Facial recontouring with lipostructure. *Clin Plast Surg* 1997;**24**:347–367.
  - 23 Coleman SR. Hand rejuvenation with structural fat, grafting. *Plast Reconstr Surg* 2002;**11**:1731–1744.
  - 24 Gatt JE. Permanent lip augmentation with serial fat grafting. *Ann Plast Surg* 1999;**42**:376–380.
  - 25 Guerrerosantos J. Autologous fat grafting for body contouring. *Clin Plast Surg* 1996;**23**:619–631.
  - 26 Roberts III TL, Weinfeld AB, Bruner TW, Nguyen K. “Universal” and ethnic ideals of beautiful buttocks are best obtained by autologous micro fat grafting and liposuction. *Clin Plast Surg* 2006;**33**:371–394.
  - 27 Tobita M, Orbay H, Mizuno H. Adipose-derived stem cells: Current findings and future perspectives. *Discov Med* 2011;**11**:160–170.
  - 28 Baer PC. Adipose-derived stem cells and their potential to differentiate into the epithelial lineage. *Stem Cells Dev* 2011;**20**:1805–1816.
  - 29 Oishi K, Noguchi H, Yukawa H, Hayashi S. Differential ability of somatic stem cells. *Cell Transplant* 2009;**18**:581–589.
  - 30 Tran TT, Kahn CR. Transplantation of adipose tissue and stem cells: Role in metabolism and disease. *Nat Rev Endocrinol* 2010;**6**:195–213.
  - 31 Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-Cortes P, Rico L, Büsscher D, Delgado M. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. *Ann Rheum Dis* 2010;**69**:241–248.
  - 32 Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. *J Cell Mol Med* 2008;**12**:553–563.
  - 33 Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, Brinchmann JE, Collas P. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. *Int J Develop Biol* 2008;**52**:1033–1042.
  - 34 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003;**112**:1821–1830.
  - 35 Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP. Regional anatomic and age effects on cell function of human adipose-derived stem cells. *Ann Plast Surg* 2008;**60**:538–544.
  - 36 Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scimè A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM. Prdm16 controls a brown fat/skeletal muscle switch. *Nature* 2008;**454**:961–967.
  - 37 Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM, Péault B, Rubin JP, Donnenberg AD. Stromal vascular progenitors in adult human adipose tissue. *Cytometry A* 2010;**77**:22–30.
  - 38 Bailey AM, Kapur S, Katz AJ. Characterization of adipose-derived stem cells: An update. *Curr Stem Cell Res Ther* 2010;**5**:95–102.
  - 39 Jeon BG, Kumar BM, Kang EJ, Ock SA, Lee SL, Kwack DO, Byun JH, Park BW, Rho GJ. Characterization and comparison of telomere length, telomerase and reverse

- transcriptase activity and gene expression in human mesenchymal stem cells and cancer cells of various origins. *Cell Tissue Res* 2011;**345**:149–161.
- 40 Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharrague P, Penicaud L, Casteilla L, Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: Comparison with bone marrow mesenchymal stem cells. *Br J Haematol* 2005;**129**:118–129.
  - 41 Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. *Transplant Proc* 2007;**39**:3358–3362.
  - 42 Greenwood H L, Singer P A, Downey G P, Martin D K, Thorsteinsdottir H, Daar A S. Regenerative medicine and the developing world. *PLoS Med* 2006;**3**: e381.
  - 43 Giampapa V. Stem cell facelift. Plastic Surgery Center Internationale. Retrieved 14 October 2010 at <http://www.youthfulneck.com/stem-cell-face-lifts.htm>
  - 44 Butler DL, Goldstein SA, Guilak F. Functional tissue engineering: the role of biomechanics. *J Biomech Eng* 2000;**122**:570-575.
  - 45 Yoshimura K, Sato K, Aoi N, Kurita M, Inoue K, Suga H, Eto H, Kato H, Hirohi T, Harii K. Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adipose-derived stem cells. *Dermatol Surg* 2008;**34**:1178–1185.
  - 46 Mesimäki K, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S, Suuronen R. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stemcells. *Int J Oral Maxillofac Surg* 2009;**38**:201–209.
  - 47 Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. *Transplant Proc* 2007;**39**:3358–3362.
  - 48 Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. *Expert Opinion Biol Ther* 2008;**8**:1417–1423.
  - 49 Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez JP, Harman RJ, Patel AN, Murphy MP, Lee RR, Minev B. Nonexpanded adipose stromal vascular fraction cell therapy for multiple sclerosis. *J Trans Med* 2009;**7**:29.
  - 50 Stillaert FB, Di Bartolo C, Hunt JA, Rhodes NP, Tognana E, Monstrey S, Blondeel PN. Human clinical experience with adipose precursor cells seeded on hyaluronic acid-based spongy scaffolds. *Biomaterials* 2008;**29**:3953–3959.
  - 51 Nambu M, Kishimoto S, Nakamura S, Mizuno H, Yanagibayashi S, Yamamoto N, Azuma R, Nakamura S, Kiyosawa T, Ishihara M, Kanatani Y. Accelerated wound healing in healing-impaired db/db mice by autologous adipose tissue-derived stromal cells combined with atelocollagen matrix. *Ann Plast Surg* 2009;**62**:317–321.
  - 52 Akita S, Akino K, Hirano A, Ohtsuru A, Yamashita S. Mesenchymal stem cell therapy for cutaneous radiation syndrome. *Health Phys* 2010;**98**:858–862.
  - 53 Lau K, Paus R, Tiede S, Day P, Bayat A. Exploring the role of stem cells in cutaneous wound healing. *Exp Dermatol* 2009;**18**:921–933.
  - 54 Blanpain C, Fuchs E. Epidermal stem cells of the skin. *Annu Rev Cell Dev Biol* 2006;**22**:339–2006.
  - 55 Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin JS, Sawicki JA, Cotsarelis G. Capturing and profiling adult hair follicle stem cells. *Nat Biotechnol* 2004;**22**:411–417.
  - 56 Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. *Circ Res* 2007;**100**:1249-1260.
  - 57 Lindroos B, Suuronen R, Miettinen S. The potential of adipose stem cells in regenerative medicine. *Stem Cell Rev and Rep* 2011;**7**:269–291.